Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

Why Achillion Pharmaceuticals Shares Soared in October

17 099 vues

Publié le

Johnson & Johnson's decision to launch a mid stage study evaluating a slate of hepatitis C drugs that includes Achillion Pharmaceuticals ACH-3102 could lead to a best-in-class hepatitis C therapy down the road.
In the following slideshow, I outline what iyou need to know about this trial and why it matters to Achillion Pharmaceuticals investors.

Publié dans : Santé, Santé & Médecine
  • +++++++++++++++++++++++++++++++Ebook pdf/fb2 == Copy link to Download https://ebooksfreede.com/load/Why_Achillion_Pharmaceuticals_Shares_Soared_in_October.pdf +++++++++++++++++++++++
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici
  • +++++++++++++++++++++++++++++++Ebook pdf/fb2 == Copy link to Download https://ebooksfreede.com/load/Why_Achillion_Pharmaceuticals_Shares_Soared_in_October.pdf +++++++++++++++++++++++
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici
  • +++++++++++++++++++++++++++++++Ebook pdf/fb2 == Copy link to Download https://ebooksfreede.com/load/Why_Achillion_Pharmaceuticals_Shares_Soared_in_October.pdf +++++++++++++++++++++++
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici
  • Unlock Her Legs is your passage way to a life full of loving and sex... read more ... ◆◆◆ http://t.cn/AiurDrZp
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici
  • If you want a girl to "chase" you, then you have to use the right "bait". We discovered 4 specific things that FORCE a girl to chase after you and try to win YOU over. copy and visiting... ◆◆◆ http://t.cn/AijLRbnO
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici

Why Achillion Pharmaceuticals Shares Soared in October

  1. 1. Why Achillion Pharmaceuticals Shares Soared in October
  2. 2. What: Achillion Pharmaceuticals is a clinical stage biotech researching hepatitis C treatment. • Odalasvir (ACH-3102) is an NS5A inhibitor. • ACH-3422 is a nucleotide NS5B inhibitor. • Sovaprevir is a protease inhibitor. Shares jumped 13.2% in October. • Co-developer Johnson & Johnson outlines plans for mid stage studies that include Achillion’s lead candidate. .
  3. 3. Achillion Pharmaceuticals
  4. 4. So What: Hepatitis C is a major market indication affecting millions of people globally. • ~3 million people in the United States. • ~9 million people in Europe. • ~1.5 million people in Japan. • Up to 170 million people worldwide.
  5. 5. So What:
  6. 6. So What: Johnson & Johnson is positioning its HCV therapy as a short duration, best-in-class solution. •Mid stage study to begin soon. • Evaluates J&J’s Olysio and AL-335, plus Achillion’s ACH-3102. • Studying safety and efficacy over four-, six-, and eight-week treatment durations.
  7. 7. Now what: Hepatitis C treatment is a multi-billion dollar market. • Top therapies annual sales run rate of >$22 billion exiting Q3.
  8. 8. Now what continued: •Increasingly competitive marketplace. • Merck FDA decision date for its HCV therapy on January 28. • Gilead Sciences application of its next-generation pan-genotype HCV therapy submitted in October 2015. • AbbVie FDA application for once-daily dosing of Viekira Pak submitted in October 2015.
  9. 9. Now what continued: •Future battle for market share to focus on short duration therapies with 95% plus cure rates. •No guarantee that J&J’s trials will succeed. •Data from phase 2 expected in 2016. •If successful and approved, Achillion will receive milestones and royalties. • Development, sales, and regulatory milestones of $1.1 billion. • Tiered royalties from mid-teens to low 20% range.
  10. 10. Now what continued: Achillion Pharmaceuticals is a high-risk company without any products on the market. • Big potential market. • Potentially shortest duration HCV therapy if approved. • Significant trial and commercialization experience via J&J. • Suitable for risk-tolerant investors able to withstand a clinical trial failure.
  11. 11. This iSecret stock could make Achillion’s pop look tiny.

×